It has been a downwards spiral for the REGN share price since August 2017 but a spike today suggests it might be worth a look? Also interesting to see that the majority of analysts are negative on the stock, even though the price is well below all of their target prices. Fancy a swim against the tide? 10 May 18 Cramer vets biotech giants Biogen, Celgene, Gilead and Regeneron for positive prospects CNBC 8 May 18 Edited Transcript of REGN earnings conference call or presentation 3-May-18 12:30pm GMT Thomson Reuters StreetEvents 6 May 18 3 Reasons Regeneron Stock Could Start Climbing Again Motley Fool
Wow that spike followed through! I think that markets dont fully understand pharmas and the risk/reward ratio associated with new treatments. I think a collective fund picking up bombed out pharmas which still have decent drugs to sell could make a fortune for someone
There are a lot of pharma groups that have bombed after their headline drugs/treatments disappointed (even just very slightly) which can sometimes mask other up and coming treatments. A pooled fund of "bombed out" pharmas with some underlying strength might be an interesting option for contrarian investors?
As pharma shares are deemed higher risk than "normal shares" it seems that investors want a greater potential reward which means pushing them to levels where they are seriously undervalued before investors show any interest. Even the ones with decent potential can get dragged into undervalued territory.
I still own a bit of this one. Have sold most of what I had above $400-500. It's one of the few biotechs that actually has earnings and pretty solid fundamentals. Not sure what it will take to get this one going again. https://seekingalpha.com/news/33577...positive-effect-early-stage-lung-cancer-study
Still a long way to go before the new drug can go on sale, and a lot that can still go wrong, but if the market gets the merest whiff that it might be successful these shares should rebound very sharply.
This one is going to be very volatile - while tempting to buy at the first sign it is turning, it might be worth waiting a little longer to be sure that the trend has changed. Not one for the faint hearted
Momentum seems to be growing again - a push above $310 would be a very bullish sign, with $350 the next possible stop?
